Reduction of Atrial Fibrillation Burden Is a Worthwhile Therapeutic Target in HFpEF

ECG heart rhythm recording on white paper showing atrial flutter, with gold stethoscope on top

In a post hoc analysis of the PARAGON-HF trial, Scott D. Solomon, MD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, and colleagues evaluated how atrial fibrillation and atrial flutter affected the results.


Icosapent Ethyl Reduces Risk of CV Events and Death in Patients With Prior MI

3D atomic rendering of icosapent ethyl

The REDUCE-IT trial found patients at risk had reduced important ischemic events with icosapent ethyl. Prakriti Gaba, MD, and Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital, and colleagues, conducted a post hoc analysis limited to patients in the trial who had a history of myocardial infarction (MI).


Age-related Remodeling of Left Atrium Associated With Subclinical Infarcts, Stroke in Absence of AF

Blue 3D rendering of male human body with echocardiography device examining the heart

Brigham researchers have demonstrated that in an older population with normal ejection fraction and sinus rhythm, age‐related left atrium reservoir dysfunction and stiffness—detectable on three-dimensional echocardiography (3DE)—were associated with higher odds of subclinical cerebral infarcts (SCIs) and stroke.


Dapagliflozin Efficacious, Safe in Type 2 Diabetes Regardless of Pre-Treatment Systolic BP

Close up of blood pressure monitor screen reading 100 over 156

SGLT2 inhibitors like dapagliflozin reduce hospitalization for heart failure and progression of diabetic nephropathy in patients with type 2 diabetes, but decrease systolic and diastolic blood pressure only minimally. Brigham researchers investigated whether their efficacy might depend on pre-treatment blood pressure.


Women, People With Low Incomes Still Have Worse Outcomes After Cardiac Surgery

Close up of female patient lying on hospital bed with ID bracelet, recovering from surgery

Over the past decade in cardiac surgery, health policy initiatives have been implemented to reduce sex and socioeconomic status disparities. To evaluate progress in the U.S., researchers at Brigham and Women’s Hospital recently conducted the largest nationally representative study to date.


Adults With TBI May Benefit From Screening for Cardiometabolic Disease, Other Comorbidities

Female doctor shows brain scan images to older male patient in hospital bed

An analysis of prospectively collected data has demonstrated that adults who sustain traumatic brain injury (TBI), regardless of age and injury severity, are at higher risk of certain cardiovascular, endocrine, neurologic, and psychiatric disorders.


Novel AI Model Helps Detect Cardiac Allograft Rejection From Endomyocardial Biopsies

Hematoxylin and eosin–stained biopsy of muscle fibers of heart myocardium

Researchers at Brigham and Women’s Hospital have created Cardiac Rejection Assessment Neural Estimator (CRANE), a form of artificial intelligence for automated screening of endomyocardial biopsy results. They describe its performance and its potential to serve as an assistive diagnostic tool.


Cocoa Extract Supplementation Shows Promise in Reducing Cardiovascular Events

Top view close up of many cocoa seeds

Researchers conducted the first rigorous, large-scale trial of long-term cocoa flavanol supplementation to prevent CVD and cancer. They found that cocoa extract supplementation led to a small but nonsignificant reduction in total cardiovascular events among older adults but significantly reduced CVD death by 27%.


The Brigham Presents Four Late-breaking Clinical Trials at ACC 2022

Three headshots of Drs. Brian Bergmark, Deepak Bhatt, and Paul Ridker

Three cardiologists from the Division of Cardiovascular Medicine at the Brigham’s Heart & Vascular Center—Brian A. Bergmark, MD, Deepak L. Bhatt, MD, MPH, and Paul M. Ridker, MD, MPH—presented a total of four late-breaking clinical trials at the American College of Cardiology’s 71st Annual Scientific Session in April.


Extended Use of Apixaban Tied to Reduced Risk of Hospitalization for Recurrent VTE

3D structure of apixaban on white background

Researchers at Brigham and Women’s Hospital recently published a nationwide U.S. study of patients who received more than 90 days of oral anticoagulation after hospitalization for VTE. They found dispensing of apixaban, versus warfarin, was associated with a modestly lower hospitalization rate for recurrent VTE.